AzurRx BioPharma Inc (AZRX) - Financial and Strategic SWOT Analysis Review
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
AzurRx BioPharma Inc (AZRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
AzurRx BioPharma Inc (AzurRx BioPharma) is a development stage biopharmaceutical company which focuses on non-systemic biologics for the treatment of patients with gastrointestinal disorders. The companys products under development include MS1819, a non-systemic yeast recombinant enzyme intended for the treatment of exocrine pancreatic insufficiency exocrine (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). MS1819 completed phase IIa trial in partnership with Mayoly which is a European Pharmaceutical company. Its pre-clinical products include AZX1103 and AZX1101 which is recombinant beta lactamases enzyme for the prevention of nosocomial (hospital-acquired) infections and antibiotic-associated diarrhea. The company has operations in France and the US. AzurRx BioPharma is headquartered in Brooklyn, New York, the US.
AzurRx BioPharma Inc Key Recent Developments
Oct 21,2020: AzurRx BioPharma announces formation of scientific advisory board
Jul 15,2020: AzurRx BioPharma: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers.
Apr 21,2020: AzurRx BioPharma receives loan under Paycheck Protection Program
Mar 02,2020: AzurRx BioPharma receives $1.13 million in 2018 CIR (French Research Tax Credit)
Jan 03,2020: AzurRx BioPharma announces appointment of Daniel Schneiderman as Chief Financial Officer
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
AzurRx BioPharma Inc (AzurRx BioPharma) is a development stage biopharmaceutical company which focuses on non-systemic biologics for the treatment of patients with gastrointestinal disorders. The companys products under development include MS1819, a non-systemic yeast recombinant enzyme intended for the treatment of exocrine pancreatic insufficiency exocrine (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). MS1819 completed phase IIa trial in partnership with Mayoly which is a European Pharmaceutical company. Its pre-clinical products include AZX1103 and AZX1101 which is recombinant beta lactamases enzyme for the prevention of nosocomial (hospital-acquired) infections and antibiotic-associated diarrhea. The company has operations in France and the US. AzurRx BioPharma is headquartered in Brooklyn, New York, the US.
AzurRx BioPharma Inc Key Recent Developments
Oct 21,2020: AzurRx BioPharma announces formation of scientific advisory board
Jul 15,2020: AzurRx BioPharma: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers.
Apr 21,2020: AzurRx BioPharma receives loan under Paycheck Protection Program
Mar 02,2020: AzurRx BioPharma receives $1.13 million in 2018 CIR (French Research Tax Credit)
Jan 03,2020: AzurRx BioPharma announces appointment of Daniel Schneiderman as Chief Financial Officer
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
TABLE OF CONTENTS
Section 1 - About the Company
AzurRx BioPharma Inc - Key Facts
AzurRx BioPharma Inc - Key Employees
AzurRx BioPharma Inc - Key Employee Biographies
AzurRx BioPharma Inc - Major Products and Services
AzurRx BioPharma Inc - History
AzurRx BioPharma Inc - Company Statement
AzurRx BioPharma Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 Company Analysis
Company Overview
AzurRx BioPharma Inc - Business Description
AzurRx BioPharma Inc - SWOT Analysis
SWOT Analysis - Overview
AzurRx BioPharma Inc - Strengths
AzurRx BioPharma Inc - Weaknesses
AzurRx BioPharma Inc - Opportunities
AzurRx BioPharma Inc - Threats
AzurRx BioPharma Inc - Key Competitors
Section 3 Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 Companys Lifesciences Financial Deals and Alliances
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
AzurRx BioPharma Inc, Recent Deals Summary
Section 5 Companys Recent Developments
Oct 21, 2020: AzurRx BioPharma announces formation of scientific advisory board
Jul 15, 2020: AzurRx BioPharma: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers.
Apr 21, 2020: AzurRx BioPharma receives loan under Paycheck Protection Program
Mar 02, 2020: AzurRx BioPharma receives $1.13 million in 2018 CIR (French Research Tax Credit)
Jan 03, 2020: AzurRx BioPharma announces appointment of Daniel Schneiderman as Chief Financial Officer
Section 6 Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List Of Tables
AzurRx BioPharma Inc, Key Facts
AzurRx BioPharma Inc, Key Employees
AzurRx BioPharma Inc, Key Employee Biographies
AzurRx BioPharma Inc, Major Products and Services
AzurRx BioPharma Inc, History
AzurRx BioPharma Inc, Subsidiaries
AzurRx BioPharma Inc, Key Competitors
AzurRx BioPharma Inc, Ratios based on current share price
AzurRx BioPharma Inc, Annual Ratios
AzurRx BioPharma Inc, Annual Ratios (Cont...1)
AzurRx BioPharma Inc, Interim Ratios
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
AzurRx BioPharma Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List Of Figures
AzurRx BioPharma Inc, Performance Chart (2015 - 2019)
AzurRx BioPharma Inc, Ratio Charts
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
RELATED REPORTS
PDL BioPharma Inc - Strategic SWOT Analysis Review
PDL BioPharma Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information
View ReportSeneca Biopharma Inc (CUR) - Financial and Strategic SWOT Analysis Review
Seneca Biopharma Inc(Seneca) formerly known as Neuralstem Inc, is a biopharmaceutical company that develops novel treatments for nervous system diseases. The company offers cell therapy treatment for ALS, ischemic stroke,
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
